Company intelligence / Profile preview
Attenuon LLC
San Diego, California, United States of America
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
The company developed cancer therapeutics, with at least one antibody targeting the uPA system that underwent humanization through XOMA's technology. Their compound Ac-PHSCN-NH2 targeting α5β1 x αvβ3 for Glioma was discontinued, and Bis-choline tetrathiomolybdate targeting SOD1 for Locally Advanced Melanoma was pending.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesSmall molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
XOMA Ltd.
Beyond the preview
Go deeper on Attenuon LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Attenuon LLC.